Diabetes
Feature
Online tool offers diabetes device information free of industry funding
“Device Finder” allows for comparisons of different device combinations based on personal preferences.
Conference Coverage
Novel drug slows progression of diabetic kidney disease
Finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, significantly reduced both renal and cardiovascular events, with good...
Conference Coverage
Experts tout immediate quadruple therapy for HFrEF patients
Recent evidence cemented four drug classes as foundational pillars of HFrEF treatment. The answer to how to start them: immediately and all at...
From the Journals
COVID-19 antibody response not reduced with diabetes
Findings provide “cautious optimism” that a COVID-19 vaccine would be expected to work as well in people with diabetes as those without.
News
Recall widens for diabetes drug metformin
More than 175 different drug combinations have been recalled since late May.
Latest News
Substance in tears could be used for diabetes monitoring
Measuring glycoalbumin in tears could someday be a way for patients with diabetes to monitor their glucose levels noninvasively.
From the Journals
Entresto halves renal events in preserved EF heart failure patients
The PARAGON-HF trial of sacubitril/valsartan in patients with heart failure with preserved ejection fraction didn’t meet its primary outcome but...
Conference Coverage
T2D treatments create tension between glycemic and cardiovascular goals
Recent society guidelines clash on whether metformin or newer drug classes should start first when treating patients with type 2 diabetes.
Conference Coverage
Empagliflozin cut PA pressures in heart failure patients
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time....
Conference Coverage
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
From the Journals
PPIs associated with diabetes risk, but questions remain
Researchers call for blood glucose testing and diabetes surveillance in long-term PPI users, but causal evidence is weak.